<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698448</url>
  </required_header>
  <id_info>
    <org_study_id>3372</org_study_id>
    <secondary_id>2018-000378-30</secondary_id>
    <nct_id>NCT03698448</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis</brief_title>
  <acronym>SMR3372</acronym>
  <official_title>A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlgiPharma AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cystic Fibrosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AlgiPharma AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo controlled study. The study has two parts:

      Dose-finding part, followed by longer term follow-up (6 months)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Randomized, double blind, placebo controlled dose-finding. Patients will be assigned
      to 1 of 3 doses OligoG, or to placebo, on top of Standard of Care. Patients will be treated
      for 12 weeks, followed by 4 weeks washout.The primary endpoint is relative change in %
      predicted FEV1. Secondary endpoints include additional spirometry parameters, exacerbation
      rate, Quality of Life, sputum rheology and microbiology, safety laboratory tests and adverse
      event reporting.

      Part 2: Randomized double-blind 6 -month study, for longer term follow-up of the dose
      identified in Part 1. New patients will be recruited in part 2, in addition to patients who
      received placebo in Part 1. In addition to the endpoints studied in Part 1, Part 2 will
      include Lung Clearance Index (LCI), chest imaging by MRI or CT, and pharmaco-economic
      parameters.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double blind, dose-finding</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo medication with identical appearance to the active drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>Change from before to after 12 weeks treatment (Part 1) and 26 weeks (Part 2)</time_frame>
    <description>the amount of air a person can forcefully exhale in one second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung Clearance Index (LCI) (Part two only)</measure>
    <time_frame>Change from before to after 26 weeks treatment</time_frame>
    <description>Lung clearance index (LCI) measured by multiple breath washout is a sensitive measure of ventilation inhomogeneity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture microbiology</measure>
    <time_frame>Change from before to after 12 weeks treatment (Part 1) and 26 weeks (Part 2)</time_frame>
    <description>Reduction in Pseudomonas Aeruginosa CFU Counts and total counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbations</measure>
    <time_frame>Change from before to after 12 weeks treatment (Part 1) and 26 weeks (Part 2)</time_frame>
    <description>Acute pulmonary exacerbations</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo DPI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17.5 mg OligoG dry powder for inhalation. 10 capsules, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27.5 mg OligoG dry powder for inhalation. 10 capsules, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>37.5 mg OligoG dry powder for inhalation. 10 capsules, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OligoG Dry powder for inhalation</intervention_name>
    <description>10 capsules Dry Powder for Inhalation, BID</description>
    <arm_group_label>High dose OligoG DPI</arm_group_label>
    <arm_group_label>Low dose OligoG DPI</arm_group_label>
    <arm_group_label>Placebo DPI</arm_group_label>
    <arm_group_label>medium dose OligoG DPI</arm_group_label>
    <other_name>Placebo dry powder for inhalation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF

          -  FEV1 at screening &gt;40 and &lt; 90% of predicted normal

          -  History of PA infection in last 12 m

          -  History of antibiotic treatment due tp PA infection (not for eradication) during last
             12 m

          -  Concomitant inhaled tobramycin, colistin, aztreonam, or levoflaxin (cycled or
             continuous)

          -  Stable CF disease

          -  Willing to remain on stable CF medication (Standard of care)

          -  Women of child-bearing potential must habe negative urine pregnany test

          -  Males &amp; females must use acceptable contraception

          -  Capable of inhaling dry powder

          -  willing to sign informed consent

          -  willing and able to follow study procedures

        Exclusion Criteria:

          -  Use of hypertonic saline &gt; twice daily

          -  Clinically significant abnormal lab findings, except CRP. In case of high GGT values,
             case will be discussed by experts before deciding

          -  History of comorbidity that may distort results or cause additional risk

          -  pulmonary exacerbation within 28 days prior to randomisation

          -  Change in CF therapy within 28 days prior to randomisation

          -  Burkholderia spp. finding within 12 m prior to screening

          -  pregnant or breast feeding females

          -  History of allergic reactions to IMP ingredients, incl milk protein

          -  Inability to perform lung function tests according to ATS/ ERS criteria

          -  Uncontrolled or unstable diseases that might limit compliance

          -  History of, or planned organ transplantation

          -  Allergic ABPA in the last 12 months prior to the screening visit

          -  Requirement for continuous oxygen supplementation

          -  Current participation in another clinical study

          -  medical condition, other than CFwhich exposes the patient to an unacceptably high risk

          -  Concurrent mlignant disease, except BCC and cervical neoplasia

          -  Clinically significant alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hilde Morris, DVM</last_name>
    <phone>+4792298921</phone>
    <email>hilde.morris@algipharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne M Graver, MSc</last_name>
    <phone>+4793041021</phone>
    <email>anne.graver@algipharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CF Zentrum Köln, Universitätskrankenhaus Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligosaccharide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

